17-10-20　ⓔ文献

  1. Kyle RA, Dirk R: Long Term follow–up of monoclonal gammopathy of undetermined significance. N Engl J Med, 2018; 378: 241–249.

  2. Rajkumar SV, Kyle RA, et al: Serum free light chain ratio in an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 2005; 106: 812–817.

  3. Fermand JP, Bridoux F, et al: Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018; 132: 1478–1485.

  4. McKenna RW, Kyle RA, et al: Plasma cell neoplasm. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed (Swerdlow SH, Campo E, et al eds), IARC Press, 2017; 241–258.

  5. Rajikumar SV, Dimopoulos MA, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014; 15: e538–548.

  6. The International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 2003; 121: 749–757.

  7. Lakshman A, Rajkumar SV, et al: Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J, 2018; 8: 59.

  8. Greipp PR, San Miguel J, et al: International staging system for multiple myeloma. J Clin Oncol, 2005; 23: 3412–3420.

  9. Sonneveld P, Goldschmidt H, et al: Bortezomib–based versus nonbortezomib–based induction treatment before autologous stem–cell transplantation in patients with previously untreated multiple myeloma: a meta–analysis of phase III randomized, controlled trials. J Clin Oncol, 2013; 31: 3279–3287.

  10. Mateos MV, Cavo M, et al: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open–label, phase 3 trial. Lancet, 2020; 395: 132–141.

  11. Kumar S, Paiva B, et al: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol, 2016; 17: e328–e346.

  12. Raje N, Terpos E, et al: Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double–dummy, randomised, controlled, phase 3 study. Lancet Oncol, 2018; 19: 370–381.

  13. Owen RG, Treon SP, et al: Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s macroglobulinemia. Semin Oncol, 2003; 30: 110–115.

  14. Treon SP, Xu L, et al: MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med, 2012; 367: 826–833.

  15. Hunter ZR, Xu L, et al: The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM–like CXCR4 mutations, and small somatic deletions associated with B–cell lymphomagenesis. Blood, 2014; 123: 1637–1646.

  16. Morel P, Duhamel A, et al: International prognostic scoring system for Waldenstrom macroglobulinemia. Blood, 2009; 113: 4163–4170.

  17. Dimopoulos MA, Kastritis E, et al: Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWMM–7 consensus. Blood, 2014; 124: 1404–1411.

  18. Bianchi G, Anderson KC, et al: The heavy chain disease: clinical and pathologic features. Oncology, 2014; 28: 45–53.

  19. Dispenziari A: POEMS Syndrome: 2019 Update on diagnosis, risk–stratification, and management. Am J Hematol. 2019; 94: 812–827.

  20. Humeniuk MS, Gertz MA, et al: Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013; 122: 68–73.

  21. Li J, Zhang W, et al: Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood, 2011; 117: 6445–6449.

  22. Cook G, Iacobelli S, et al: High–dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub–committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017; 102: 160–167.

  23. Retamozo S, Brito–Zeron P, et al: Cryoglobulinemic disease. Oncology. 2013; 27: 1098–1105.

  24. Roccatello D, Sciascia S, et al: The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti–CD20 monoclonal antibodies and direct antiviral agents. Oncotarget, 2017; 8: 41764–41777.

  25. Giuggioli D, Sebastiani M, et al: Treatment of HCV–Related Mixed Cryoglobulinemia. Curr Drug Targets, 2017; 18: 794–802.